Virginia Clinical Trials Report — April 2026

For Virginians considering participation in clinical research, April 2026 brings a critical window of opportunity, especially for those looking to join studies with rapidly approaching enrollment deadlines. Across the Commonwealth, a significant number of trials are slated to conclude recruitment within the next 90 days, totaling 128 studies. This urgency extends to healthy volunteers, with 13 of these rapidly closing trials still actively seeking participants without specific health conditions. If you've been contemplating contributing to medical advancements, now is the time to explore these options before they close.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on heart health, respiratory issues, and mental well-being are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Heart failure
• Asthma
• Mental health issue
• Deep venous thrombosis
• Chronic pain
• Lower extremity conditions
• Breast cancer
• Advanced solid tumor
• Atrial fibrillation

Groundbreaking Research Arrives: Obesity, Cancer, and Asthma Innovations

This month, Virginia welcomes 19 new clinical trials, offering participants the chance to engage with cutting-edge treatments and diagnostic tools. This is a slight increase from the 17 new trials that opened in March 2026, indicating continued growth in research opportunities across the state. Several high-profile Phase 2 and 3 studies from major pharmaceutical companies are among these new additions, addressing a range of health challenges from metabolic disorders to advanced cancers.

• Novo Nordisk A/S is sponsoring NCT07533175, "AMAZE 2," a Phase 3 study investigating a new medicine, NNC0487-0111, for individuals with excess body weight and Type 2 diabetes. This substantial trial aims to enroll 630 participants to evaluate the safety and effectiveness of this weekly injectable treatment.
• Another significant study from Novo Nordisk A/S is NCT07509307, "AMAZE 6," a Phase 3 trial exploring NNC0487-0111 in people with excess body weight and knee osteoarthritis. This study seeks 400 participants to assess the medicine's effect on weight loss and pain reduction.
• Incyte Corporation is launching NCT07522073, a Phase 3 study evaluating chemotherapy with or without INCB161734 for previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial is designed for 588 participants.
• For those with severe asthma, Kinaset Therapeutics Inc is initiating NCT07532265, a Phase 2 dose-ranging study of Frevecitinib (KN-002). This trial will evaluate the efficacy and safety of the treatment over a 12-week period in 512 participants whose asthma is not controlled with standard medications.
• Novartis Pharmaceuticals is offering an open-label extension study, NCT07517263, to evaluate the long-term safety and tolerability of Pelacarsen (TQJ230). This Phase 3 study is significant for its large scope, planning for 5,700 participants who have completed the double-blind parent study.
• Caliway Biopharmaceuticals Co., Ltd. is sponsoring NCT07526974, a Phase 3 study titled "SUPREME-02," investigating the efficacy and safety of CBL-514 Injection for reducing abdominal subcutaneous fat. This randomized, double-blinded, placebo-controlled study aims to enroll 320 participants.
• The National Scoliosis Center is leading NCT07527611, a registry for the "Development of a Conservative Care and Bracing Registry (CCBR)," which plans to enroll 280 participants to gather evidence-based guidelines for idiopathic scoliosis.
• A pragmatic, prospective, observational registry, NCT07535268, "REPRESENT-PF Registry," is evaluating the safety and effectiveness of PFA for atrial fibrillation in underrepresented minority patients, with 275 participants.

Expanding Opportunities: New Conditions and Diverse Participation

This month's new trials are exploring a range of conditions, from common metabolic issues to more specialized areas. New studies are targeting:

• Prediabetes
• Obesity
• Overweight
• Cirrhosis
• Crohn's disease (CD)
• Diabetes mellitus
• Early onset scoliosis
• Hepatic encephalopathy
• Hot flashes

The types of interventions being studied are varied, with drug trials leading the way, accounting for 11 of the new trials. Other intervention types include behavioral (2), device (2), biological (1), and procedure (1) studies. The remaining 3 trials fall under the 'Other' category.

Participation in clinical trials is open to a wide range of individuals. Of the 19 new trials launched this month, 17 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is open to children, 2 are female-only, and 1 is male-only, indicating specific demographic needs for certain studies.

For individuals without a specific medical condition, there are significant opportunities to contribute. 2 of the new trials this month are actively seeking healthy volunteers. Across Virginia, a total of 137 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Both academic institutions and industry sponsors are driving research efforts in Virginia. Notable academic sponsors this month include Virginia Polytechnic Institute and State University, while industry leaders like Novo Nordisk A/S, Eli Lilly and Company, Incyte Corporation, and Kinaset Therapeutics Inc are also launching significant studies.

Virginia's Research Footprint: Accessibility Across the Commonwealth

Virginia's clinical research landscape is robust, with a total of 1,857 clinical trials currently recruiting across 68 cities and 1,069 research sites. This broad distribution ensures accessibility for a wide range of Virginians.

This month's new research initiatives are spread across several key locations. The top cities for new trial openings include:

• Fairfax (4 new trials)
• Charlottesville (4 new trials)
• Richmond (4 new trials)
• Blacksburg (2 new trials)
• Salem
• Williamsburg
• Arlington
• Winchester
• Falls Church
• Newport News

While metropolitan areas like Fairfax, Charlottesville, and Richmond continue to be hubs for new research, the presence of new trials in cities like Blacksburg, Salem, and Williamsburg highlights the statewide reach of clinical research opportunities.

As we move further into spring, the focus will likely remain on the ongoing enrollment in these significant Phase 2 and 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Virginia.